Hernando Chong, DO
Adult Medicine · Miami, FLNPI 1386613586
Payments from drug & device makers
Across 460 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$1K
- AstraZeneca$778
- Lilly USA, LLC$728
- AbbVie$590
- GSK$565
- plus $3K from 34 others
What the payments were for
- Food & beverage$9,231100%
- Gifts$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 75 | $1,655 |
| Novo Nordisk | 49 | $1,447 |
| AstraZeneca | 43 | $778 |
| Lilly USA, LLC | 47 | $728 |
| AbbVie(2 entities) | 39 | $590 |
| GSK | 29 | $565 |
| Abbott | 24 | $476 |
| Pfizer | 22 | $337 |
| Exact Sciences | 14 | $313 |
| Boehringer Ingelheim | 14 | $249 |
| Merck | 13 | $217 |
| Sanofi-aventis U.S. LLC | 10 | $177 |
| Biohaven Pharmaceuticals, Inc. | 3 | $173 |
| Johnson & Johnson | 8 | $160 |
| Boston Scientific | 1 | $149 |
| Novartis | 7 | $113 |
| Amarin Pharma, Inc. | 6 | $105 |
| Dexcom, Inc. | 6 | $103 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 6 | $93 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Bayer | 5 | $80 |
| Astellas Pharma US Inc | 4 | $70 |
| Sanofi Pasteur Inc. | 3 | $66 |
| Medtronic | 3 | $54 |
| Saluda Medical Americas, Inc. | 2 | $49 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| Corcept Therapeutics | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Optinose US, Inc. | 2 | $35 |
| Edwards Lifesciences | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| Lifescan, Inc. | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Ascend Therapeutics US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$473
- Repatha$373
- RYBELSUS$243
- WATCHMAN FLX$149
- NURTEC ODT$123
- AIMOVIG$115
How this compares
$9,242 in reported general payments places this provider in the 90th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $257,462 |
| JardianceEmpagliflozin | 113 | $151,864 |
| MounjaroTirzepatide | 101 | $129,324 |
| EliquisApixaban | 43 | $56,041 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $41,423 |
| FarxigaDapagliflozin Propanediol | 19 | $30,667 |
| LinzessLinaclotide | 27 | $27,695 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $25,816 |
| Repatha SureclickEvolocumab | 18 | $23,004 |
| ProliaDenosumab | 13 | $22,420 |
| XareltoRivaroxaban | 13 | $17,273 |
| Atorvastatin Calcium | 608 | $6,595 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,224 |
| Rosuvastatin Calcium | 430 | $6,159 |
| Levothyroxine Sodium | 389 | $5,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,447 | $257,462144 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $249 | $177,679129 claims |
| Lilly USA, LLCMounjaro | $728 | $129,324101 claims |
| PfizerEliquis | $337 | $56,04143 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $565 | $46,51469 claims |
| AbbVieLinzess, Synthroid | $590 | $32,88897 claims |
| AstraZenecaFarxiga | $778 | $30,66719 claims |
| AmgenProlia | $1,655 | $22,42013 claims |
| Johnson & JohnsonXarelto | $160 | $17,27313 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $5,664389 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Miami
- Nelson GonzalezMiami$1.6M
- Francisco Gonzalez AbreuMiami$774K
- Maria de la TorreMiami$685K
- Steven SantiagoMiami$290K
- Ariadna ValdesMiami$4K
- Lucky FloresMiami Lakes$4.2M
- Lidia BermudezHialeah$2.6M
- Linda MartinezDoral$2.1M
- Victor SilvaTampa$1.2M
- Tammy DsouzaKissimmee$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.